I’ve been saying this forever…
One of the greatest barriers in the development of treatments for certain mental (and even physical) illnesses has been the public’s perception of them.
I’m referring to cannabis and “magic” mushrooms (specifically psilocybin — the active psychedelic compound in them).
The public’s view of them as anything other than dangerous, mind-altering drugs has been held for decades. And that’s kept any research extremely limited in terms of any medical benefits they may have.
In last month’s issue, I updated you on a potentially groundbreaking development where Juva Life goes. But just last week, as we “went to press,” some news broke on what would appear to be a major change in the government’s policy.
So today I want to share some more potentially good news where ALL of our medical recommendations go. But first a little background…
These Substances Historically Get a Bad Rap
The perception of Schedule I controlled substances as anything but dangerous, mind-altering drugs has become a huge wall to climb. Not so much because of what they are, but because of the length of time they’ve been demonized.
But they weren’t always that way.
From the late 1940s all the way into the early 1960s, psychedelics were studied for a wide range of psychiatric applications ranging from schizophrenia to alcoholism — often with positive results.
As reported in one study, “Strikingly, all alcoholism experiments using psychedelics, controlled or not, helped 50% of patients” not to mention their effectiveness treating neurosis or anxiety.
By the mid-60s however, these substances were becoming highly politicized and associated with the social trends of the day. To be fair, any drug is not without its risks. But there was a certain amount of questionable science involved when it came to its prohibition.
Not only were psychedelics being deemed unsafe on a number of levels, but the “counterculture” that accompanied them as recreational drugs was suddenly portrayed as a threat to the social fabric of society. And despite the questionable evidence, the media of the day propagated these views.
By the end of the 1960s, psychedelics were deemed to be more dangerous than beneficial and in 1970, with the passage of the Controlled Substances Act, they (along with marijuana) were classified as Schedule I substances — where they’ve remained for the past 50 years.
Now, however, there appears to be some excellent “breaking” news happening on the medical research front — for all our Schedule I companies.
What’s Suddenly Changed?
It looks like the DEA, one of two federal agencies empowered to determine which substances are on the controlled substances list, is finally having some second thoughts about their potential research value.
Just last week they filed with the Federal Register (that’s the Government’s “daily journal” of everything they’re up to) to increase the amount of controlled substance production that would directly impact several of the companies that we have been recommending.
“DEA is proposing significant increases to the APQs (Aggregate Production Quotas) of the schedule I substances psilocybin, psilocin, marihuana, and marihuana extract, which are directly related to increased interest by DEA registrants in the use of hallucinogenic controlled substances for research and clinical trial purposes.”– The Federal Register
Specifically they are looking to expand production of “marihuana” from 1.5 million grams to 2 million grams — a 30% increase.
Their production increases for psychedelics are even higher…
Psilocin has a recommended production increase from 50 to 1000 grams (that’s a 1,900% increase) and Psilocybin’s recommended increase goes from 30 grams to 1,500 grams (a 4,900% percent increase!)
While these are far from “mass production” numbers, they are not insignificant.
So What Does This Mean?
First, understand that this does not mean the profit dam is suddenly bursting.
The DEA’s listing in the Federal Register right now is simply a notice of intent with requests for comments.
Schedule I controlled substances are defined as having a high potential for abuse, zero accepted medical uses, and are determined to be unsafe even under medical supervision.
So that remains a pretty high “perception” hurdle to clear .
But given the size of the increases — specifically in these substances — we’d say it’s a big step in the right direction as far as we are concerned.
These are “ground floor” stocks which means the big breakout moves may still be months, or even years away. But with these developments, their futures look a lot brighter.
We’ll keep you posted on any developments in this area.
Make the trend your friend,
Co-founder, Streetlight Equity